<?xml version="1.0"  encoding="windows-1252"?>
<rss version="2.0">
	<channel>
		<title>Buprenorphine: What's New</title>
		<link>http://buprenorphine.samhsa.gov/bwns/</link>
		<description>New information from SAMHSA's Buprenorphine Web Site</description>
		<language>en-us</language>
		<pubDate>Fri, 2 May 2008 08:30:00 EDT</pubDate>
		<lastBuildDate>Mon, 26 Jan 2009 08:30:00 EDT</lastBuildDate>
		<docs>http://blogs.law.harvard.edu/tech/rss</docs>
		<managingEditor>info@buprenorphine.samhsa.gov</managingEditor>
		<webMaster>webmaster@buprenorphine.samhsa.gov</webMaster>


<item>
			<title>Generic Subutex Approved</title>
			<link>http://www.Roxane.com</link>
			<description>
				<![CDATA[Roxane Laboratories, Inc. announces the launch of buprenorphine 1/2 HCl sublingual tablets Columbus, OH - October 8, 2009. 
Roxane Laboratories, Inc. announced today the approval of its Abbreviated New Drug Application (ANDA) for Buprenorphine HCl Sublingual Tablets, 
2mg and 8mg by the U.S. Food and Drug Administration. The product is available in bottles of 30 for immediate shipment to wholesalers and pharmacies nationwide.

Roxane Laboratories' Buprenorphine HCl Sublingual Tablets are AB rated to SUBUTEX® (buprenorphine HCl) tablets. Annual sales of SUBUTEX® are approximately $67.7 Million.

Full prescribing information for Buprenorphine HCl Sublingual Tablets is available on the Roxane Laboratories website at www.Roxane.com or upon request by calling Roxane Laboratories 
Technical Product Information at 1.800.962.8364.]]>
			</description>
			<pubDate>16 Nov 2009 15:00:00 EST</pubDate>
			<guid>http://www.Roxane.com</guid>
		</item>


		<item>
			<title>SAMHSA Issues Nationwide Public Health Alert Concerning Life Threatening Risk Posed by Cocaine Laced with Veterinary Anti-Parasite Drug</title>
			<link>http://buprenorphine.samhsa.gov/bwns/LevNcocneDC-09.pdf</link>
			<description>
				<![CDATA[The Substance Abuse and Mental Health Services Administration (SAMHSA) is alerting medical professionals, substance abuse treatment centers 
and other public health authorities about the risk that substantial levels of cocaine may be adulterated with levamisole-a veterinary anti-parasitic drug. There have been approximately 
20 confirmed or probable cases of agranulocytosis (a serious, sometimes fatal blood disorder), including two deaths, associated with cocaine adulterated with levamisole. The number of 
reported cases is expected to increase as information about cocaine adulterated with levamisole is disseminated.  Use this link to go to the letter.]]>
			</description>
			<pubDate>22 Sep 2009 15:00:00 EST</pubDate>
			<guid>http://buprenorphine.samhsa.gov/bwns/LevNcocneDC-09.pdf</guid>
		</item>


<item>
			<title>Get the Latest on Substance Abuse and Mental Health </title>
			<link>http://buprenorphine.samhsa.gov/</link>
			<description>
				<![CDATA[Dear Colleague:
			Did you know that you can receive updates on materials and resources related to substance abuse and mental health issues?
<br>
By enrolling in SAMHSA&rsquo;s eNetwork, a free service, you can stay current with the latest grant announcements, data, and publications that will help you serve your community. Once you <a href="https://service.govdelivery.com/service/multi_subscribe.html?code=USSAMHSA&origin=http://www.samhsa.gov/enetwork/success.aspx">Join the eNetwork</a>, you can choose your areas of interest and receive the information that is important to you.
]]>
			</description>
			<pubDate>21 Aug 2009 13:59:00 EDT</pubDate>
			<guid>http://buprenorphine.samhsa.gov/bwns/DrClg-SubRx-0409.pdf</guid>
		</item>


		<item>
			<title>SAMHSA and DEA issue letter on prescribing Suboxone/Subutex in opioid treatment programs</title>
			<link>http://buprenorphine.samhsa.gov/bwns/DrClg-SubRx-0409.pdf</link>
			<description>
				<![CDATA[Did you know that you can receive updates on materials and resources related to substance abuse and mental health issues?
<br>
By enrolling in SAMHSA&rsquo;s eNetwork, a free service, you can stay current with the latest grant announcements, data, and publications that will help you serve your community. Once you <a href="https://service.govdelivery.com/service/multi_subscribe.html?code=USSAMHSA&origin=http://www.samhsa.gov/enetwork/success.aspx">Join the eNetwork</a>, you can choose your areas of interest and receive 
<br>For example, we can send you regular email updates on:
<ul> 
<li><a href="http://www.samhsa.gov/grants/">Grants and funding opportunities</a></li>
<li><a href="http://www.samhsa.gov/Campaigns_programs/campaigns_alpha.aspx">Prevention and treatment campaigns</a></li>
<li><a href="http://oas.samhsa.gov/">Reports and statistical data</a></li>
<li><a href="http://www.samhsa.gov/shin/">Publications</a></li>
<li><a href="http://nrepp.samhsa.gov/">Evidence-based practices</a></li></ul>
Subscribers are also the first to receive <a href="http://www.samhsa.gov/samhsaNewsletter/default.aspx">SAMHSA News</a>, the agency&rsquo;s award-winning newsletter published online six times a year.</span>
the information that is important to you. By enrolling in SAMHSA&rsquo;s eNetwork, a free service, you can stay current with the latest grant announcements, data, and publications that will help you 
serve your community. Once you <a href="https://service.govdelivery.com/service/multi_subscribe.html?code=USSAMHSA&origin=http://www.samhsa.gov/enetwork/success.aspx">Join the eNetwork</a>, you can choose your areas of interest and receive the information that is important to you.]]>
			</description>
			<pubDate>18 August 2009 13:00:00 EST</pubDate>
			<guid>http://buprenorphine.samhsa.gov/</guid>
		</item>


		<item>
			<title>New Resource Available for Nurses on Buprenorphine</title>
			<link>http://buprenorphine.samhsa.gov/bwns/Dear Nursing Professionals-TAP30.pdf</link>
			<description>
				<![CDATA[Dear Nursing Professionals: 
				The Center for Substance Abuse Treatment (CSAT), Substance Abuse and Mental Health Services 
				Administration (SAMHSA), is releasing a Technical Assistant Publication (TAP 30) titled 
				"Buprenorphine: A Guide for Nurses." This publication is intended to provide nurses, including 
				registered nurses (RNs), licensed practical nurses (LPNs), nurse practitioners (NPs), and Advanced 
				Practice Nurses (APNs) with current information about buprenorphine products-Suboxone® 
				(buprenorphine and naloxone) and Subutex® (buprenorphine)-for the pharmacological treatment of 
				opioid addiction. This Guide can also serve as a resource to enable nurses working with physician 
				prescribers to improve treatment outcomes for individuals receiving buprenorphine treatment for 
				opioid addiction.]]>
			</description>
			<pubDate>25 Mar 2009 15:07:00 EST</pubDate>
			<guid>http://buprenorphine.samhsa.gov/bwns/Dear Nursing Professionals-TAP30.pdf</guid>
		</item>

		
		<item>
			<title>New Resource Available on Medication-Assisted Treatment for Opioid Addiction</title>
			<link>http://buprenorphine.samhsa.gov/bwns/tip43_curriculum.pdf</link>
			<description>
				<![CDATA[The Substance Abuse and Mental Health Services Administration’s (SAMHSA's) Center for 
				Substance Abuse Treatment (CSAT) is pleased to announce the availability of Medication-Assisted 
				Treatment for Opioid Addiction in Opioid Treatment Programs Inservice Training, a new training
				manual based on Treatment Improvement Protocol (TIP) 43. This new manual provides detailed training
				information aimed at introducing substance abuse treatment professionals to medication-assisted
				treatment for opioid addiction in opioid treatment programs. The manual describes opioid use
				disorders; provides assessment, treatment planning, pharmacology, and dosing information; and
				presents evidence-based best practices for treatment.]]>
			</description>
			<pubDate>23 Jan 2009 16:08:00 EST</pubDate>
			<guid>http://buprenorphine.samhsa.gov/bwns/tip43_curriculum.pdf</guid>
		</item>


		<item>
			<title>Federal Register Notice</title>

			<link>http://buprenorphine.samhsa.gov/bwns/NPRM-06-19-2009.pdf</link>
			<description>
				<![CDATA[On June 19, SAMHSA issued a notice of proposed rulemaking on the use of buprenorphine products in SAMHSA-certified opioid treatment programs (OTPs). If adopted, the proposal would remove the time in treatment dispensing requirements for buprenorphine products used to treat patients in OTPs. The dispensing restrictions would remain in effect for patients treated with methadone. The closing date for comments on this proposal is August 19, 2009.]]>
			</description>
			<pubDate>7 Jul 2009 13:30:00 EST</pubDate>
			<guid>http://buprenorphine.samhsa.gov/bwns/NPRM-06-19-2009.pdf</guid>

		</item>

		<item>
			<title>Results from New Clinical Trial of Buprenorphine in Young Adults</title>
			<link>http://jama.ama-assn.org/cgi/content/full/300/17/2003</link>
			<description>
				<![CDATA[This clinical trial evaluates the efficacy of continuing Buprenorphine-Naloxone for 12
				weeks versus detoxification for opioid-addicted youth. The number of patients younger than 18 years
				was too small to analyze separately, but overall, patients in the detox group had higher
				proportions of opioid-poisitive urine test results at weeks 4 and 8 but not at week 12.]]>
            </description>
			<pubDate>10 Nov 2008 11:44:00 EST</pubDate>
			<guid>http://jama.ama-assn.org/cgi/content/full/300/17/2003</guid>
		</item>   
		<item>
			<title>SAMHSA and NIDA Convene Summit on Buprenorphine Treatment</title>
			<link>http://buprenorphine.samhsa.gov/bwns/presentations.html</link>
			<description>
				<![CDATA[The Summit convened February 21-22, 2008, in Washington, D.C. to bring together experts in
				epidemiology, pharmacology, toxicology, and addiction treatment in order to build upon the findings
 				of the previous summits in 2003 and 2005.  Participants assessed the successes, progress and
				continued barriers to access to opioid treatment with buprenorphine.  Presentations identified best
				practices and useful clinical supports to enhance the quality of treatment.  Participants identified
				strategies to address emerging issues and concerns. SAMHSA and NIDA will prepare a report on the
				proceedings.]]>
			</description>
			<pubDate>29 Feb 2008 09:22:00 EST</pubDate>
			<guid>http://buprenorphine.samhsa.gov/bwns/presentations.html</guid>
		</item>
		<item>
			<title>Update Physician Contact Information</title>
			<link>http://buprenorphine.samhsa.gov/pls/bwns/updtcntct2$.startup</link>
			<description>
				<![CDATA[Physicians, you can now update your own contact information. If you have given permission to
				post contact information in the Buprenorphine Physician and Treatment Program Locator, the
				information will be updated there too.]]>
			</description>
			<pubDate>29 Feb 2008 12:09:56 EST</pubDate>
			<guid>http://buprenorphine.samhsa.gov/pls/bwns/updtcntct2$.startup</guid>
		</item>
	</channel>
</rss>